Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (3r,5as,6r,8as,9r,12s,12ar)-3,6,9-trimethyloctahydro-3,12-epoxypyrano(4,3-j)-1,2-benzodioxepin-10(3h)-one
2. Arteannuin
3. Artemisinine
4. Artemisininum
5. Huanghuahaosu
6. Qing Hao Su
7. Qinghaosu
8. Quing Hau Sau
9. Quinghaosu
1. Qinghaosu
2. 63968-64-9
3. Huanghuahaosu
4. Artemisinine
5. Artemisine
6. (+)-artemisinin
7. Artemisinina
8. Artemisininum
9. Artemisinin [inn]
10. Qing Hau Sau
11. Nsc 369397
12. Chebi:223316
13. Octahydro-3,6,9-trimethyl-3,12-epoxy-12h-pyrano(4,3-j)-1,2-benzodioxepin-10(3h)-one
14. 9rmu91n5k2
15. Qinghosu
16. Quing Hau Sau
17. Astemisinin
18. (1r,4s,5r,8s,9r,12s,13r)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one
19. (3r,5as,6r,8as,9r,12s,12ar)-3,6,9-trimethyloctahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepin-10(3h)-one
20. (3r,5as,6r,8as,9r,12s,12ar)-octahydro-3,6,9-trimethyl-3,12-epoxy-12h-pyrano(4,3-j)-1,2-benzodioxepin-10(3h)-one
21. Qing Hau Su
22. Qinghaosu [chinese]
23. Artemisinine [french]
24. Artemisininum [latin]
25. Artemisinina [spanish]
26. (+)-arteannuin
27. Qing Hau Sau [chinese]
28. Mfcd00081057
29. Artemisia Annua L., Extract
30. (1r,4s,5r,8s,9r,12s,13r)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0^{4,13}.0^{8,13}]hexadecan-10-one
31. (3r,5as,6r,8as,9r,12s,12ar)-3,6,9-trimethyloctahydro-3,12-epoxypyrano(4,3-j)(1,2)benzodioxepin-10(3h)-one
32. (3r,5as,6r,8as,9r,12s,12ar)-octahydro-3,6,9-trimethyl-3,12-epoxy-12h-pyrano[4,3-j]-1,2-benzodioxepin-10(3h)-one
33. 1,5,9-trimethyl-(1r,4s,5r,9r,12s,13r)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one
34. Smr000578089
35. Sr-01000802560
36. Gnf-pf-5341
37. Artemsinin
38. Brn 4194670
39. Unii-9rmu91n5k2
40. Artemesinin
41. Artesin
42. Nsc-369397
43. Qinghaosu,artemisinine
44. Spectrum_001351
45. Artemisinin [mi]
46. Prestwick0_000498
47. Prestwick1_000498
48. Prestwick2_000498
49. Prestwick3_000498
50. Spectrum2_001512
51. Spectrum3_001549
52. Spectrum4_000721
53. Spectrum5_001098
54. Artemisinin [inci]
55. Ec 700-290-5
56. Artemisinin [mart.]
57. Schembl60304
58. Artemisinin [usp-rs]
59. Artemisinin [who-dd]
60. Artemisinin [who-ip]
61. Bspbio_000395
62. Bspbio_002998
63. Kbiogr_000982
64. Kbioss_001831
65. Mls001097650
66. Mls001304036
67. Mls002153846
68. Divk1c_000656
69. Spbio_001583
70. Spbio_002316
71. Bpbio1_000435
72. Chembl269671
73. Gtpl9954
74. Dtxsid2040652
75. Kbio1_000656
76. Kbio2_001831
77. Kbio2_004399
78. Kbio2_006967
79. Kbio3_002498
80. Ninds_000656
81. Hms2090i17
82. Hms2096d17
83. Hms2267n09
84. Hms3269l13
85. Hms3413p13
86. Hms3677p13
87. Hms3713d17
88. Pharmakon1600-01503042
89. 3,12-epoxy-12h-pyrano[4,3-j]-1,2-benzodioxepin-10(3h)-one, Octahydro-3,6,9-trimethyl-, (3r,5as,6r,8as,9r,12s,12ar)-
90. Bcp02096
91. Hy-b0094
92. Zinc8143788
93. Artemisininum [who-ip Latin]
94. Bdbm50088447
95. Nsc758216
96. Akos024457231
97. Ccg-220498
98. Cs-1794
99. Db13132
100. Lmpr0103190003
101. Nsc-758216
102. Idi1_000656
103. (3r,5as,6r,8as,9r,12s,12ar)-3,6,9-trimethyloctahydro-12h-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10(3h)-one
104. 3,12-epoxy-12h-pyranol(4,3-j)-1,2-benzodioxepin-10(3h)-one, Octahydro-3,6,9-trimethyl-, (3-alpha,5a-beta,6-beta,8a-beta,9-alpha,12-beta,12ar*)-(+)-
105. As-12692
106. S1282
107. 968a649
108. Q426921
109. Sr-01000802560-2
110. Sr-01000802560-3
111. Sr-01000802560-4
112. Brd-k13112821-001-08-3
113. Brd-k13112821-001-17-4
114. 2ab44f63-5d0f-424a-aa3f-24062f9c1ced
115. (3r,5as,6r,8as,9r,12s,12ar)-3,6,9-trimethyloctahydro-3,12-epoxypyrano(4,3-j )-1,2-benzodioxepin-10(3h)-one
116. (3r,5as,6r,8as,9r,12s,12ar)-3,6,9-trimethyloctahydro-3h-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10(12h)-one
Molecular Weight | 282.33 g/mol |
---|---|
Molecular Formula | C15H22O5 |
XLogP3 | 2.8 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 0 |
Exact Mass | 282.14672380 g/mol |
Monoisotopic Mass | 282.14672380 g/mol |
Topological Polar Surface Area | 54 Ų |
Heavy Atom Count | 20 |
Formal Charge | 0 |
Complexity | 452 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 7 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Anti-Infective Agents
Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)
P - Antiparasitic products, insecticides and repellents
P01 - Antiprotozoals
P01B - Antimalarials
P01BE - Artemisinin and derivatives, plain
P01BE01 - Artemisinin
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
OT-101 (trabedersen) has completed seven clinical trials including one phase 2 trial in COVID and two phase 2 trials in brain cancer and against pancreatic cancer. It has pediatric designation for a rare form of pediatric brain cancer known as DIPG.
Lead Product(s): Trabedersen,Artemisinin
Therapeutic Area: Infections and Infectious Diseases Brand Name: OT-101
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: BARDA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding October 12, 2022
Lead Product(s) : Trabedersen,Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : BARDA
Deal Size : Undisclosed
Deal Type : Funding
Oncotelic Awarded BARDA Funding for Development of OT-101 for long COVID
Details : OT-101 (trabedersen) has completed seven clinical trials including one phase 2 trial in COVID and two phase 2 trials in brain cancer and against pancreatic cancer. It has pediatric designation for a rare form of pediatric brain cancer known as DIPG.
Brand Name : OT-101
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 12, 2022
Details:
Through this partnership, and through HempStreet’s extensive distribution reach and key institutional partnerships, Indian patients will now have access to these medicines, starting with CimetrA (Artemisinin), which had an immediate need.
Lead Product(s): Artemisinin,Curcumin,Boswellia Serrata
Therapeutic Area: Infections and Infectious Diseases Brand Name: CimetrA
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: MGC Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 07, 2022
Lead Product(s) : Artemisinin,Curcumin,Boswellia Serrata
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : MGC Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
HempStreet Announces Partnership with MGC Pharma to Revolutionise Global Phytomedicine Sector
Details : Through this partnership, and through HempStreet’s extensive distribution reach and key institutional partnerships, Indian patients will now have access to these medicines, starting with CimetrA (Artemisinin), which had an immediate need.
Brand Name : CimetrA
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 07, 2022
Details:
The study includes 150 adult patients with a confirmed SARS-CoV-2 infection, at least 4 weeks of long-COVID symptoms, and a Post Covid Functional Score (PCFS) between one and four. ArtemiC Support is administered orally, in a dosage of 5 drops three times daily for 6 weeks.
Lead Product(s): Artemisinin,Curcumin,Frankincense
Therapeutic Area: Infections and Infectious Diseases Brand Name: ArtemiC
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: MGC Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2021
Lead Product(s) : Artemisinin,Curcumin,Frankincense
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : MGC Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The study includes 150 adult patients with a confirmed SARS-CoV-2 infection, at least 4 weeks of long-COVID symptoms, and a Post Covid Functional Score (PCFS) between one and four. ArtemiC Support is administered orally, in a dosage of 5 drops three time...
Brand Name : ArtemiC
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 21, 2021
Details:
PulmoHeal/ ArtiVeda has proven active against COVID-19 in ARTI-19 clinical trial (A Prospective, Randomized, Multi-center, Open label, Interventional Study to Evaluate the Safety and Efficacy of Artemisinin 500 mg capsule in Treatment of Adult Subjects with COVID-19).
Lead Product(s): Artemisinin
Therapeutic Area: Infections and Infectious Diseases Brand Name: PulmoHeal
Study Phase: Phase IVProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2021
Lead Product(s) : Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Pulmoheal™/ Artiveda™ Is Clinically Active Against Mild and Moderate Covid-19
Details : PulmoHeal/ ArtiVeda has proven active against COVID-19 in ARTI-19 clinical trial (A Prospective, Randomized, Multi-center, Open label, Interventional Study to Evaluate the Safety and Efficacy of Artemisinin 500 mg capsule in Treatment of Adult Subjects w...
Brand Name : PulmoHeal
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 24, 2021
Details:
Manus Bio has received a third funding award from the Bill & Melinda Gates Foundation to accelerate the development of a scalable and cost-effective production method for artemisinin, a key therapeutic for treating malaria.
Lead Product(s): Artemisinin
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Bill & Melinda Gates Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding April 01, 2021
Lead Product(s) : Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Bill & Melinda Gates Foundation
Deal Size : Undisclosed
Deal Type : Funding
Manus Bio Awarded Additional Funding To Support Its Artemisinin Development Program
Details : Manus Bio has received a third funding award from the Bill & Melinda Gates Foundation to accelerate the development of a scalable and cost-effective production method for artemisinin, a key therapeutic for treating malaria.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 01, 2021
Details:
Mateon has completed the enrollment of its sentinel Part 1 and Part 2 COVID-19 patients which allows for the continuing expansion to the targeted 18 patients in part 1 and 18 patients in part 2. OT-101 is an antisense against the host TGF-β protein.
Lead Product(s): Trabedersen,Artemisinin
Therapeutic Area: Infections and Infectious Diseases Brand Name: OT-101
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Oncotelic
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2021
Lead Product(s) : Trabedersen,Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Oncotelic
Deal Size : Not Applicable
Deal Type : Not Applicable
Mateon’s Update on C001 - Global Study for Ot-101 Against Covid-19
Details : Mateon has completed the enrollment of its sentinel Part 1 and Part 2 COVID-19 patients which allows for the continuing expansion to the targeted 18 patients in part 1 and 18 patients in part 2. OT-101 is an antisense against the host TGF-β protein.
Brand Name : OT-101
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 08, 2021
Details:
The Malta facility will create a European manufacturing hub for ArtemiCTM with the ability to scale production to meet expected growing demand following positive clinical trial results.
Lead Product(s): Artemisinin,Curcumin,Boswellia Serrata
Therapeutic Area: Infections and Infectious Diseases Brand Name: ArtemiC
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Malta Enerprises
Deal Size: $3.7 million Upfront Cash: $3.7 million
Deal Type: Funding December 22, 2020
Lead Product(s) : Artemisinin,Curcumin,Boswellia Serrata
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Malta Enerprises
Deal Size : $3.7 million
Deal Type : Funding
MGC Pharmaceuticals Receives Cash Grant to Help Establish ArtemiCTM Productioninn Malta
Details : The Malta facility will create a European manufacturing hub for ArtemiCTM with the ability to scale production to meet expected growing demand following positive clinical trial results.
Brand Name : ArtemiC
Molecule Type : Small molecule
Upfront Cash : $3.7 million
December 22, 2020
Details:
Interim Results reported to date demonstrate ArtemiCTM has met all primary end points for safety and efficacy, and FDA primary endpoint of sustained clinical recovery of COVID-19 patients.
Lead Product(s): Artemisinin,Curcumin,Frankincense
Therapeutic Area: Infections and Infectious Diseases Brand Name: ArtemiC
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2020
Lead Product(s) : Artemisinin,Curcumin,Frankincense
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
MGC Pharmaceuticals Provides ArtemiCTM Phase II Clinical Trial Results Update
Details : Interim Results reported to date demonstrate ArtemiCTM has met all primary end points for safety and efficacy, and FDA primary endpoint of sustained clinical recovery of COVID-19 patients.
Brand Name : ArtemiC
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 07, 2020
Details:
The trial is assessing the safety and efficacy of the natural anti-inflammatory formulation ArtemiCTM, a natural supplement formula based on Artemisinin and Curcumin (along with supporting ingredients Vitamin C and Boswellia serrata) on COVID-19 Patients.
Lead Product(s): Artemisinin,Curcumin,Frankincense
Therapeutic Area: Infections and Infectious Diseases Brand Name: ArtemiC
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2020
Lead Product(s) : Artemisinin,Curcumin,Frankincense
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
MGC Pharmaceuticals Expands ArtemiC™ Phase II Clinical Trial on COVID-19 Patients in Israel and ...
Details : The trial is assessing the safety and efficacy of the natural anti-inflammatory formulation ArtemiCTM, a natural supplement formula based on Artemisinin and Curcumin (along with supporting ingredients Vitamin C and Boswellia serrata) on COVID-19 Patients...
Brand Name : ArtemiC
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 28, 2020
Details:
ARTI19 is designed to rapidly establish the clinical efficacy of Artemisinin in mild and moderate COVID-19 patients. In-vitro, the medical grade version of the supplement has proven potency and safety similar to Remdesivir with an EC50 = 0.45 ug/ml and Safety Index = 140.
Lead Product(s): Artemisinin
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Mateon Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 20, 2020
Lead Product(s) : Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Mateon Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Details : ARTI19 is designed to rapidly establish the clinical efficacy of Artemisinin in mild and moderate COVID-19 patients. In-vitro, the medical grade version of the supplement has proven potency and safety similar to Remdesivir with an EC50 = 0.45 ug/ml and S...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 20, 2020
CAS Number :
End Use API : Artemisinin
About The Company : Manufacturers and Exporters of speciality fine chemicals, speciality solvents, Pharma Intermediates, Agro Intermediates, Cosmetic ingredients and nutraceutical ...
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?